Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
Author:
Publisher
Frontiers Media SA
Subject
Pharmacology (medical),Pharmacology
Reference55 articles.
1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discov.,2013
2. Targeting NADPH oxidases for the treatment of cancer and inflammation;Bonner;Cell Mol. Life Sci.,2012
3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med.,2015
4. The underlying basis for obesity: Relationship to cancer;Bray;J. Nutr.,2002
5. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer;Carbone;N. Engl. J. Med.,2017
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer;Journal of Translational Medicine;2024-06-18
2. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations;BMC Pulmonary Medicine;2023-11-29
3. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma;Frontiers in Oncology;2023-03-07
4. Adenocarcinomas of the Lung and Neurotrophin System: A Review;Biomedicines;2022-10-10
5. Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes;Frontiers in Genetics;2022-08-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3